Saturday, April 20, 2024
HomeFunding Boston-based Bicara Therapeutics Secures $165m in Series C Round Funding

[Funding alert] Boston-based Bicara Therapeutics Secures $165m in Series C Round Funding

Boston-based Bicara Therapeutics secures $165m in series C round funding. The financing was co-led by Braidwell LP and TPG, which is investing in the company through TPG Life Sciences Innovations (TPG LSI) .

Boston-based Bicara Therapeutics secures $165m in series C round funding. The financing was co-led by Braidwell LP and TPG, which is investing in the company through TPG Life Sciences Innovations (TPG LSI) .

The Rise Fund, with additional new investors including Deerfield Management, Fairmount, Aisling Capital and a leading biotechnology investor associated with one of the largest alternative asset managers.

Read also – Provision IAM Raises Funding from Curql to Drive Growth

Proceeds from the Series C financing will be used to support the continued advancement of Bicara’s lead product candidate, BCA101, a first-in-class bifunctional EGFR/TGF-β inhibitor that is currently in clinical development for multiple cancer types including frontline human papillomavirus (HPV)-negative, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), advanced squamous non-small cell lung cancer (SqNSCLC) and cutaneous squamous cell carcinoma.

Read also – NYC-based Dimensional Energy Secures $20M in Series A Round Funding

Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics said, “Momentum at Bicara is increasing following our BCA101 Phase 1/1b data presentations at key 2023 medical meetings,” “Our proof-of-concept data in frontline HPV-negative R/M HNSCC, a very difficult patient population to treat, underscore the promise of BCA101 as a new precision therapeutic option for these patients. With additional data readouts anticipated in 2024, we remain excited about the overall potential of BCA101 to help patients with HPV-negative R/M HNSCC, as well as other solid tumor types. We are thrilled to partner with this syndicate of new and existing leading healthcare investors, who share in our vision for BCA101 and Bicara’s bifunctional antibody platform.”

Dr. Ng. “I am excited to join Bicara’s board of directors said, “Bicara’s Phase 1/1b dose expansion study of BCA101 has delivered encouraging, clinically meaningful interim results and offers an excellent foundation from which to continue to build Bicara into a leading oncology company at such an important time and look forward to working with this talented management team and distinguished board of directors to advance new treatments for cancer patients.”

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.

Read also – CA-based Chalk Secures $10M in Seed Funding

The Company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular